![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4.675 | 4.35 | 5.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.52 | 9.41M |
Date | Subject | Author | Discuss |
---|---|---|---|
08/9/2020 07:08 | Synairgen plc Positive interim analysis of SNG001 in COPDSource: UK Regulatory (RNS & others)TIDMSNGRNS Number : 2832YSynairgen plc08 September 2020Press releaseSynairgen plc('Synairgen' or the 'Company')Synairgen announces positive data from interim analysis of SNG001 trial in COPD patients - SNG001 well tolerated in this older population with a significant co-morbidity (COPD) - Strong interferon driven antiviral biomarker response - Data support future progression of SNG001 for exacerbating COPD patients - Positive data supportive of SNG001 COVID-19 programme Southampton, UK - 8 September 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces positive data from the interim analysis of its exploratory Phase II clinical trial of inhaled SNG001 in Chronic Obstructive Pulmonary Disease (COPD) patients with a confirmed respiratory viral infection.Key findings -- Safety SNG001 was well tolerated during the treatment period in a study population that was elderly (mean age 66 years) and suffering from reduced respiratory function, as measured by forced expiratory volume in one second (FEV1) (59% of predicted value). The percentage of on-treatment adverse events was similar in the placebo and SNG001 treatment groups (48.1% versus 45.6%, respectively), with treatment-related adverse events being more frequent in the placebo group (25%) compared to the SNG001 group (15.8%). This safety data add to the safety database for SNG001, supporting Synairgen's interactions with regulatory agencies in respect of COVID-19, where older age and poor lung function are risk factors. -- Antiviral activity Over the treatment period, lung antiviral responses to viral infection were significantly enhanced in patients receiving SNG001 compared to those on placebo, as assessed by measuring increases in the gene expression of interferon beta-dependent antiviral biomarkers MX1 (p= | nortic 007 | |
08/9/2020 07:06 | Excellent news! | ![]() dave444 | |
08/9/2020 07:06 | Mmmm.... RNS ..... not what i was expecting ! | ![]() amaretto1 | |
08/9/2020 07:00 | Posted by ‘dafad’ on LSE: How plentiful interferon production may help bats withstand C-19. | ![]() wetdream |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions